World's Best Scientists 2026 revealed!
Eva Hellström-Lindberg

Eva Hellström-Lindberg

D-Index & Metrics

Medicine

D-Index
86
Citations
43939
World Ranking
13863
National Ranking
260

Overview

Eva Hellström-Lindberg is affiliated with Karolinska University Hospital in Sweden, conducting research primarily in the fields of medicine and biochemistry, genetics, and molecular biology. Their work emphasizes hematology, genetics, molecular biology, immunology, and cancer research.

The scientist's research focuses on several main topics, including:

  • Acute Myeloid Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Hematopoietic Stem Cell Transplantation
  • Cancer Genomics and Diagnostics
  • RNA modifications and cancer
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment

Eva Hellström-Lindberg has published extensively, with key recent papers including:

  • International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data, 2022, published in Blood
  • Molecular International Prognostic Scoring System for Myelodysplastic Syndromes, 2022, published in NEJM Evidence
  • Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia, 2022, published in Blood
  • Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome, 2022, published in Nature Cell Biology
  • Myelodysplastic syndromes: moving towards personalized management, 2020, published in Haematologica

The scientist frequently collaborates with other researchers, including:

  • Luca Malcovati
  • Elsa Bernard
  • Maria Creignou
  • Pierre Fenaux
  • Martin Jädersten

Their research has been disseminated widely in notable publication venues such as:

  • Leukemia Research
  • Blood
  • Leukemia
  • HemaSphere
  • Blood Advances

Best Publications

  • The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

    James W. Vardiman;Jüergen Thiele;Daniel A. Arber;Richard D. Brunning

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

    Pierre Fenaux;Ghulam J. Mufti;Eva Hellstrom-Lindberg;Valeria Santini

  • Clinical and biological implications of driver mutations in myelodysplastic syndromes.

    Elli Papaemmanuil;Moritz Gerstung;Luca Malcovati;Sudhir Tauro

  • Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts

    E. Papaemmanuil;M. Cazzola;J. Boultwood;L. Malcovati

  • Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

    Pierre Fenaux;Ghulam J. Mufti;Eva Hellström-Lindberg;Valeria Santini

  • Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

    Luca Malcovati;Eva Hellström-Lindberg;David Bowen;Lionel Adès

  • TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

    Martin Jädersten;Leonie Saft;Alexander Smith;Austin Kulasekararaj

  • Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

    Luca Malcovati;Elli Papaemmanuil;David T. Bowen;Jacqueline Boultwood

  • A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.

    Eva Hellström-Lindberg;Nina Gulbrandsen;Greger Lindberg;Tomas Ahlgren

  • A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    Pierre Fenaux;Aristoteles Giagounidis;Dominik Selleslag;Odile Beyne-Rauzy

  • Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

    Elsa Bernard;Yasuhito Nannya;Robert P. Hasserjian;Sean M. Devlin

  • Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies.

    Eva Hellström-Lindberg

  • Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

    Pierre Fenaux;Pierre Fenaux;Uwe Platzbecker;Ghulam J. Mufti;Guillermo Garcia-Manero

  • Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

    Ghulam J. Mufti;John M. Bennett;Jean Goasguen;Barbara J. Bain

  • Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

    Eva Hellström-Lindberg;Tomas Ahlgren;Yves Beguin;Magnus Carlsson

  • Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

    Eva Hellström‐Lindberg;Robert Negrin;Richard Stein;Sanford Krantz

  • Pseudouridylation of tRNA-Derived Fragments Steers Translational Control in Stem Cells

    Nicola Guzzi;Maciej Cieśla;Phuong Cao Thi Ngoc;Stefan Lang

  • Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome

    Martin Jädersten;Luca Malcovati;Ingunn Dybedal;Matteo Giovanni Della Porta

  • Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level

    Lars Nilsson;Ingbritt Åstrand-Grundström;Ingbritt Åstrand-Grundström;Ingrid Arvidsson;Ingrid Arvidsson;Björn Jacobsson;Björn Jacobsson

Frequent Co-Authors

Pierre Fenaux
Pierre Fenaux Université Paris Cité
Mario Cazzola
Mario Cazzola University of Pavia
Guillermo Sanz
Guillermo Sanz Hospital Universitari i Politècnic La Fe
Ghulam J. Mufti
Ghulam J. Mufti King's College London
Andrea Pellagatti
Andrea Pellagatti University of Oxford
Ulrich Germing
Ulrich Germing Heinrich Heine University Düsseldorf
Alan F. List
Alan F. List Precision BioSciences
David Bowen
David Bowen Royal Prince Alfred Hospital
Lennart Nilsson
Lennart Nilsson Karolinska Institute
Peter J. Campbell
Peter J. Campbell Wellcome Sanger Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare degrees and pathways can broaden your options in the medical field. Many professionals are now seeking flexible, online learning opportunities to advance their careers or transition into new roles.

For registered nurses hoping to further their education, you might consider an rn to bsn without clinicals program. These allow working nurses to earn a Bachelor’s degree without the need for additional in-person clinical requirements.

Those aiming for leadership or advanced practice roles should look into online dnp programs. Many of these offerings are accelerated, letting you complete your Doctor of Nursing Practice in less time. Some students also prefer to explore the easiest dnp programs, which can provide a more streamlined and accessible path to a doctoral degree.

If you are interested in starting your nursing career quickly, you may want to learn what is the fastest way to become an lpn. Fast-track and online LPN programs can help you enter the workforce faster, opening up entry-level opportunities in healthcare.

Best Scientists Citing Eva Hellström-Lindberg

Trending Scientists

Recently Published Articles